Innate Pharma SA (IPHA) ニュース

Innate Pharma reçoit l’autorisation de l’agence américaine du médicament d’initier le développement clinique d’IPH4502, son ADC ciblant Nectine-4, dans les tumeurs solides

IPH4502 est un nouveau conjugué anticorps-médicament (ADC) ciblant Nectine-4 et différencié grâce à un inhibiteur de topoisomérase I comme agent...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH61011...

Form S-8 - Securities to be offered to employees in employee benefit plans

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca...

Innate Pharma organise une conférence téléphonique pour présenter ses résultats financiers et l’avancée de son portefeuille au premier semestre 2024

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd'hui qu'elle organisera...

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Arvind Sood, EVP...

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team...